Golden
CytomX Therapeutics

CytomX Therapeutics

A biotechnology company that develops Probodies, proteolytically-activated antibodies to treat cancer.

CytomX Therapeutics is a privately funded and publicly traded biotechnology company based in the South San Francisco, California and was founded in 2008 by Fred Gluck and Patrick Daugherty. It is a clinical stage oncology-focused biopharmaceutical company pioneering in a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.



Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. CytomX's product pipeline includes cancer immunotherapies against clinically-validated targets. CX-072 and CX-188 are PD-L1 targeting Probody therapeutic. CX-2009 is an in-class Probody drug conjugate targeting CD166. All three are owned wholly by CytomX.



The company is also collaborating with other biopharmaceutical companies including AbbVie, Amgen, Bristol-Myers Squibb Company, and ImmunoGen, Inc. BMS-986249 is a CTLA-4 targeting Probody therapeutic partnered with Bristol Myers Squibb. CX-2029 is a DC71 targeting Probody drug conjugate partnered with AbbVie.



All products, except CX-188 are in various Phase 1/2 clinical trial progression. CX-2009 is currently being evaluated in its clinical trial, while CX-2009 and BMS-986249 are enrolling patients for the clinical studies.

Timeline

Funding rounds

1 Result
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Alison Joly

Senior VP, Program and Alliance Management



Charles S. Fuchs

Director



Danielle Olander

Senior VP, Talent and Administrative Operations



Debanjan Ray

CFO



Eric Kanowsky

Investor



Fred Gluck

Co-Founder & Director



George Holbrook

Investor



Hoyoung Huh

Chairman



Jim West

Employee



John Petote

Investor



John Scarlett

Director



Lloyd A. Rowland, Jr.

Senior VP, General Counsel, Secretary, & Chief Compliance Officer



Matthew Young

Director



Mike Panesis

Investor



Olga Vasiljeva

Employee



Patrick Daugherty

Founder



Rachel Humphrey

Chief Medical Officer



Sean A. McCarthy

President & CEO



Sridhar Viswanathan

Senior VP, Process Sciences and Manufacturing Operations



W. Michael Kavanaugh

Chief Scientific Officer & Head of Research and Non-Clinical Development



Further reading

Title
Author
Link
Type
Date

CytomX Therapeutics Announces Senior Management Appointments

CytomX Therapeutics Inc.

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References